Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus CLINDAMYCIN PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus CLINDAMYCIN PHOSPHATE.
CLEOCIN HYDROCHLORIDE vs CLINDAMYCIN PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin hydrochloride is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, thereby interfering with peptide bond formation and chain elongation.
Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
150-450 mg orally every 6 hours (oral capsules). Maximum dose: 1.8 g/day.
600 mg IV every 8 hours or 300-450 mg PO every 6 hours
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 to 3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8.5 hours. No significant change in renal impairment.
Terminal half-life 2-4 hours (prolonged to 8-12 hours in severe hepatic impairment; unchanged in renal failure)
Approximately 10% of the active drug is excreted in urine as unchanged clindamycin; about 3.6% in feces; remainder is metabolized primarily in liver. Renal excretion accounts for ~10% of elimination, biliary/fecal route accounts for ~90% including metabolites.
Renal 10% unchanged, fecal/biliary 90% as metabolites (mostly inactive)
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic